Floatz logo

(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE

Post Traumatic Stress Disorder

Queen's UniversitySmall moleculePhase 4 / ApprovedActive
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
64/ 100
Competitive Position
89/ 100

Competitive context

21 Active assets in the Post Traumatic Stress Disorder cohort.

Asset / SponsorPhaseRating
Sertraline
Yang I. Pachankis, PhD
Phase 4BB
Paroxetine
University of Washington
Phase 4BB
Cipralex
New York State Psychiatric Institute
Phase 4BB
Methylphenidate
VA Office of Research and Development
Phase 4BB
Duloxetine
Yang I. Pachankis, PhD
Phase 4B

View all 44 →

Same molecule, other indications

(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE is also rated in:

major depressive disorderDormant
BBB
Indicative ·
74 / 100
View asset →
major depressive disorderDormant
BBB
Indicative ·
74 / 100
View asset →
chronic pain syndromeDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →